# Brenus Pharma

Source: https://onco.cc/companies/brenus-pharma/  
OnCo record `brenus-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Brenus Pharma makes an off-the-shelf immunotherapy from inactivated, specially prepared cancer cells, designed to teach the immune system to recognise bowel cancer that has spread.

## Summary

Brenus Pharma, with offices in Clermont-Ferrand and Lyon, France, develops off-the-shelf in vivo immunotherapies from banked cancer cell lines that are stimulated to display cancer-associated proteins, tagged with a hapten and inactivated before being given to patients. Its lead candidate STC-1010 is in a first-in-human phase 1/2 trial (BreAK-CRC001) in unresectable locally advanced or metastatic microsatellite-stable colorectal cancer (NCT06934538); the first patients were dosed in September 2025 and the FDA accepted an IND in May 2026. In July 2026 it announced an EUR 11 million (USD 12.6 million) Series A extension, bringing total capital raised since inception to EUR 38 million (USD 43.5 million). Its first registered cancer trial, NCT06934538, was posted on ClinicalTrials.gov in April 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Clermont-Ferrand
- Type: biotech
- Website: https://www.brenus-pharma.com/

## Notes

- Company website and July 2026 release read on 29 October 2026. Founding year not stated on the pages read. The original Series A was not read and is not recorded.

## Sources

- Official website: https://www.brenus-pharma.com/
- Series A extension release, July 2026: https://www.brenus-pharma.com/articles/brenus-pharma-series-a-extension-new-investors
- News: https://www.brenus-pharma.com/news

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- trials: [First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer](https://onco.cc/trials/nct06934538/)

---
JSON: https://onco.cc/api/v1/entities/brenus-pharma.json